Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $10.00 Consensus Target Price from Analysts

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) has earned an average recommendation of “Moderate Buy” from the five analysts that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $10.00.

A number of equities research analysts have recently issued reports on AMRX shares. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price target for the company in a research report on Friday, September 6th. Piper Sandler raised their price objective on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. Truist Financial upped their target price on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Wednesday, October 2nd. Finally, StockNews.com cut shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday.

Amneal Pharmaceuticals Stock Up 0.8 %

NASDAQ:AMRX opened at $7.75 on Friday. The stock has a market capitalization of $2.40 billion, a price-to-earnings ratio of -11.40 and a beta of 1.12. Amneal Pharmaceuticals has a 52 week low of $5.01 and a 52 week high of $9.48. The firm has a 50 day moving average of $8.43 and a 200 day moving average of $7.92.

Insider Buying and Selling at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, SVP Jason B. Daly sold 43,657 shares of the firm’s stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $8.61, for a total value of $375,886.77. Following the completion of the transaction, the senior vice president now owns 13,665 shares of the company’s stock, valued at $117,655.65. This trade represents a 76.16 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 26.56% of the stock is currently owned by corporate insiders.

Institutional Trading of Amneal Pharmaceuticals

Large investors have recently modified their holdings of the stock. Franklin Resources Inc. grew its stake in Amneal Pharmaceuticals by 4.9% during the 3rd quarter. Franklin Resources Inc. now owns 89,887 shares of the company’s stock worth $778,000 after purchasing an additional 4,178 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Amneal Pharmaceuticals by 11.1% in the 3rd quarter. Geode Capital Management LLC now owns 3,786,671 shares of the company’s stock valued at $31,511,000 after buying an additional 378,136 shares during the period. Barclays PLC boosted its stake in shares of Amneal Pharmaceuticals by 134.1% in the 3rd quarter. Barclays PLC now owns 296,384 shares of the company’s stock valued at $2,466,000 after buying an additional 169,756 shares during the period. Y Intercept Hong Kong Ltd acquired a new position in shares of Amneal Pharmaceuticals during the third quarter worth about $311,000. Finally, Wellington Management Group LLP purchased a new stake in shares of Amneal Pharmaceuticals during the third quarter worth approximately $687,000. Hedge funds and other institutional investors own 31.82% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.